Lineage Cell Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LCTX and other ETFs, options, and stocks.

About LCTX

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery.

CEO

Brian M. Culley

CEOBrian M. Culley

Employees

Employees77

Headquarters

Carlsbad, California

HeadquartersCarlsbad, California

Founded

1990

Founded1990

Employees

Employees77

LCTX Key Statistics

Market cap

378.89M

Market cap378.89M

Price-Earnings ratio

-5.56

Price-Earnings ratio-5.56

Dividend yield

—

Dividend yield—

Average volume

1.40M

Average volume1.40M

High today

$1.68

High today$1.68

Low today

$1.61

Low today$1.61

Open price

$1.68

Open price$1.68

Volume

722.07K

Volume722.07K

52 Week high

$2.09

52 Week high$2.09

52 Week low

$0.3651

52 Week low$0.3651

Stock Snapshot

The current Lineage Cell Therapeutics(LCTX) stock price is $1.63, with a market capitalization of 378.89M. The stock trades at a price-to-earnings (P/E) ratio of -5.56.

On 2025-12-29, Lineage Cell Therapeutics(LCTX) stock traded between a low of $1.61 and a high of $1.68. Shares are currently priced at $1.63, which is +1.2% above the low and -3.0% below the high.

The Lineage Cell Therapeutics(LCTX)'s current trading volume is 722.07K, compared to an average daily volume of 1.4M.

In the last year, Lineage Cell Therapeutics(LCTX) shares hit a 52-week high of $2.09 and a 52-week low of $0.37.

Analyst ratings

86%

of 7 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own LCTX. This list is generated using Robinhood data, and it’s not a recommendation.